Gliomas are the most common human primary brain tumours, and are thought to be derived from neuroectodermal glial cells. The most malignant form of the gliomas, glioblastomas, are thought to be derived from lower grade astrocytomas through the activation of oncogenes and inactivation of tumour-suppressor genes (Nigro et al., 1989; Venter et al., 1991; Collins and James, 1993) . Enhanced expression of platelet-derived growth factor (PDGF) and its receptors occurs in glioma cells and tissues, suggesting the presence of autocrine and paracrine growth stimulation (Nister et al., 1991; Hermanson et al., 1992) . Epidermal growth factor (EGF) receptor genes are frequently amplified, and found in 40-50% of glioblastomas (Libermann et al., 1985; Wong et al., 1987) .
Bone morphogenetic proteins (BMPs) are a family of proteins that were originally identified to induce bone and cartilage formation in ectopic skeletal sites in vivo (Reddi, 1992; Wozney, 1989) . More than ten proteins are found to belong to the BMP family so far, e.g. BMP-2 to -6 (Wozney et al., 1988; Celeste et al., 1990) , osteogenic protein (OP)-1 and -2 (which are also referred to as respectively) (Ozkaynak et al., 1990 and growth/ differentiation factor (GDF)-5 to -7 (Storm et al., 1994) . BMPs have various distribution patterns and exert their biological effects on different cell types. A previous study on the expression of OP-1 in different mouse tissues revealed that OP-1 is expressed in kidney, heart and at a lower level in brain. BMPs stimulate proteoglycan synthesis in chondroblasts, as well as alkaline phosphatase activity and collagen synthesis in osteoblasts (Vukicevic et al., 1989) , chemotaxis of monocytes (Cunningham et al., 1992) and differentiation of neural cells Perides et al., 1992 Perides et al., , 1993 .
BMPs also play important roles in the early stages of embryogenesis (Lyons et al., 1991; Kingsley, 1994a) .
The BMP family of proteins belongs to the transforming growth factor-0 (TGF-f5) superfamily (ten Dijke et al., 1994a; Massague et al., 1994; Kingsley, 1994b chromium potassium sulphate gelatin-coated glass slides. One of the serial sections from each specimen was stained with haematoxylin-eosin to verify the histopathological diagnosis. For detection of OP-1, we could not use the tissues, since the OP-1 antibody failed to work on sections from formalin-fixed and paraffin-embedded tissues. Therefore, three fresh-frozen glioblastoma multiforme specimens were taken at the time of surgery and fixed in acetone at -20°C, until analysed by immunohistochemistry. They were stained with all four antibodies.
Preparation of antibodies
Specific rabbit antisera against BMPR-IA, BMPR-IB and ActR-I were made against synthetic peptides corresponding to the intracellular juxtamembrane parts of the type I receptors as described previously (ten Dijke et al., 1994b) . Antisera were affinity purified using CNBr-activated Sepharose CL-4B (Pharmacia-LKB) columns with immobilised peptides as described previously (Waltenberger et al., 1993a) . A monoclonal antibody against recombinant human OP-1 was generated as described previously (Vukicevic et al., 1994) .
Immunohistochemistry
Sections were deparaffinised, rehydrated in descending alcohol dilutions and immersed in phosphate-buffered saline (PBS). All slides were treated with 0.001% trypsin (T8003, Sigma) in PBS for 5 min. ABC peroxidase immunohistochemistry was performed essentially as described previously (Waltenberger et al., 1993b) . The antibodies against BMPR-IA, BMPR-IB, ActR-I and OP-1 were used at a concentration of 3 jug ml-'. Tissues were then incubated with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame CA, USA), followed by incubation with Vectastain ABC Elite complex (Vector Laboratories). For the monoclonal antibody against OP-1, biotinylated antimouse IgG (Vector) was used. The immunoreaction was visualised by using 3-amino-9-ethylcarbazole (Merck) The distribution of BMPR-IA, BMPR-IB and ActR-I in glioma tissues was examined using immunohistochemical techniques. Positive immunohistochemical staining for BMPR-IA was found in the cytoplasm of spindle-shaped tumour cells surrounding the blood vessels (Figure 1 a, Table I ). Strong immunoreactivity for BMPR-IB was found in the advancing edge of the cell-rich tumour areas ( Figure  lb) , in gemistocytic and other scattered tumour cells in the reactive areas. In contrast, astrocytoma, oligoastrocytoma and gliosis tissues showed weak or no staining (Table I) . A distinct increase of BMPR-IB in tumour cells was observed in GBM compared with astrocytomas (n = 16, P< 0.005), and with gliosis (n= 13, P<0.001). In contrast, BMPR-IA staining was moderate and ActR-I staining was only weakly expressed in some of the GBM tissues (Figure ic) . In gliotic tissues only weak expression of ActR-I or BMPR-I was seen in a few cases (Table I) . A weakly significant correlation of ActR-I staining with the degree of malignancy was found when all three groups were taken together (n =21, P < 0.05). Very weak or no staining was detected in the areas of endothelial proliferation and extracellular matrix for BMPR-IB and BMPR-IA as well as for ActR-I. The control tissue sections, where primary antibodies were omitted, failed to stain positively, excluding the possibility of non-specific reactions by endogenous peroxidase, or detection systems. Specificities of the affinitypurified antibodies as well as the monoclonal OP-1 antibody were confirmed by nearly complete fading of the stainings when primary antibodies were blocked with the corresponding antigens.
Expression of OP-I in glioblastoma tissue OP-1 was also detected in tissue sections of malignant glioma as revealed by staining with a monoclonal antibody against human OP-1. In all three glioblastoma multiforme tissues investigated, moderate staining was observed in the cytoplasm of glioma cells in high cell density areas ( Figure  Id) .
Expression of BMP receptors in malignant glioma N Yamada et al " 627 tochemistry. Using the monoclonal antibody against human OP-1, we found that OP-1 was expressed in all three glioma cell lines (Table II, Figure Ih ). All these cell lines stained strongly positive by the BMPR-IA antibody (Table II, Figure  le) and weakly by the BMPR-IB antibody ( Figure If) . However, no staining was detected by the ActR-I antibody ( Figure Ig) . Specificity of the antibodies to BMPR-IA and BMPR-IB was confirmed by quenching of the staining by preincubation of the antibodies with the corresponding peptides (not shown).
Effects of OP-I on the growth of malignant glioma cell lines OP-1 inhibited the growth of malignant glioma cell lines, U251MGsp, U343MGa and U1240MG as well as that of MvILu, which was used as comparison; 20-40% inhibition of [3H]thymidine incorporation was obtained at 10 nM OP-1 (Figure 2 ).
Discussion
Members of the TGF-,B superfamily have been shown to inhibit the growth of various cell types (McCarthy and Bicknell, 1993; Wallen et al., 1989; Matzuk et al., 1992) , however the effect of OP-1 on growth regulation has not been fully characterised. It has been reported that OP-1 stimulates the growth of osteoblasts (Sampath et al., 1992) , whereas it inhibits the growth of MvlLu cells . The growth-inhibitory activities of OP-1 and activin A on MvlLu cells are approximately 100-fold lower than that of TGF-,ll . Here, we show that inhibits the growth of human malignant glioma cell lines. Interestingly, these cells are resistant to the growth-inhibitory action of TGF-,B (Yamada et al., 1995) , suggesting that the signalling pathways for growth inhibition are not entirely common for OP-1 and TGF-fi.
BMPR-IA is strongly expressed in glioma cell lines, whereas BMPR-IB is expressed at lower levels. In contrast, GBM tissues showed moderate to strong expression of BMPR-IB, and low to moderate expression of BMPR-IA. Expression of BMPR-Is was weaker in the low-grade astrocytoma, and very low in gliosis. Thus, a positive correlation between the malignancy grade of glioma and the expression of BMPR-IB was observed. On the other hand, the expression of ActR-I, which binds OP-1 but not BMP-4 (ten Dijke et al., 1994c), was weak in malignant gliomas. These results suggest that glioma cells may be more responsive to the action of BMPs, compared with the cells in non-tumourous tissues and low-grade gliomas. Moreover also expressed in the glioma cells and tissues, suggesting that autocrine or paracrine control of cellular growth might take place in the glioma tissues. Northern blot analyses revealed that BMP-2 to -6 or OP-I to -2 are not expressed in the normal brain (Sampath et al., 1992) . Other members in the BMP family, e.g. GDF-1 (Lee, 1991) and dorsalin-l (Basler et al., 1993) , are expressed in the normal nervous systems. The significance of the enhanced expression of OP-1 in the high-grade glioma for the malignant properties of the cells remains to be elucidated. Despite the fact that BMPs inhibit glioma cell growth, it is possible that they contribute to the malignant phenotype. Thus, BMPs act in the interaction of epithelial cells and mesenchyma (Lyons et al., 1991) , and stimulate chemotaxis (Cunningham et al., 1992) . They can also induce extracellular matrix and adhesion proteins (Vukicevic et al., 1989; Paralkar et al., 1992; Perides et al., 1992 Perides et al., , 1993 that are important in the invasive growth of tumour. Thus, it is possible that BMPs have stimulatory effects on glioma progression, directly or indirectly, through these or other mechanisms.
BMPR-II and ActR-IIs, which can function as type II receptors for BMPs, are expressed in brain (Mathews and Vale, 1991; Rozenzweig et al., 1995) . It remains to be seen whether they are expressed in glioma. Elucidation of the functional roles of BMPs in glioma awaits further studies.
